Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes

被引:26
|
作者
Waalkes, Adam [1 ]
Penewit, Kelsi [1 ]
Wood, Brent L. [1 ]
Wu, David [1 ]
Salipante, Stephen J. [1 ]
机构
[1] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
关键词
CELL TRANSPLANTATION; SOMATIC MUTATIONS; RARE MUTATIONS; AML; GENOME; QUANTIFICATION; EVOLUTION; RELAPSE; CLONES; TP53;
D O I
10.3324/haematol.2017.169136
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The identification of minimal residual disease is the primary diagnostic finding which predicts relapse in patients treated for acute myeloid leukemia. Ultrasensitive detection of minimal residual disease would enable better patient risk stratification and could open opportunities for early therapeutic intervention. Herein we apply single molecule molecular inversion probe capture, a technology combining multiplexed targeted sequencing with error correction schemes based on molecular barcoding, in order to detect mutations identifying minimal residual disease with ultrasensitive and quantitative precision. We designed a single molecule molecular inversion probe capture panel spanning > 50 kb and targeting 32 factors relevant to acute myeloid leukemia pathogenesis. We demonstrate linearity and quantitative precision over 100- fold relative abundance of mutant cells (1 in 100 to 1 in 1,500), with estimated error rates approaching 1 in 1,200 base pairs sequenced and maximum theoretical limits of detection exceeding 1 in 60,000 mutant alleles. In 3 of 4 longitudinally collected specimens from patients with acute myeloid leukemia, we find that single molecule molecular inversion probe capture detects somatic mutations identifying minimal residual disease at substantially earlier time points and with greater sensitivity than clinical diagnostic approaches used as current standard of care (flow cytometry and conventional molecular diagnosis), and identifies persisting neoplastic cells during clinical remission. In 2 patients, single molecule molecular inversion probe capture detected heterogeneous, subclonal acute myeloid leukemia populations carrying distinct mutational signatures. Single molecule molecular inversion probe technology uniquely couples scalable target enrichment with sequence read error correction, providing an integrated, ultrasensitive approach for detecting minimal residual disease identifying mutations.
引用
收藏
页码:1549 / 1557
页数:9
相关论文
共 50 条
  • [41] Impact of pretransplant minimal residual disease detection by flow cytometry in acute myeloid leukemia
    Perez, E.
    Lopez-Godino, O.
    Cabrero, M.
    Labrador, J.
    Alonso, S.
    Perez, J. J.
    Lopez-Corral, L.
    Vazquez, L.
    Gonzalez, M.
    Hernadez, J. M.
    Puig, N.
    Diez-Campelo, M.
    Martin, A.
    Mateos, M. V.
    Paiva, B.
    del Canizo, M. C.
    San Miguel, J.
    Caballero, M. D.
    Vidriales, M. B.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S238 - S239
  • [42] High resolution banding technique in detection of minimal residual disease in acute myeloid leukemia
    Elbordini, M
    Elghandour, A
    Abdelaziz, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 618S - 618S
  • [43] Minimal Residual Disease in Acute Myeloid Leukemia: Prognostication and Pitfalls
    Stein, Eytan M.
    JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (08) : 485 - +
  • [44] Minimal residual disease in acute myeloid leukemia: biological features
    Preudhomme, Claude
    Plesa, Adriana
    Roumier, Christophe
    HEMATOLOGIE, 2020, 26 : 5 - 18
  • [45] Minimal residual disease in acute myeloid leukemia: coming of age
    Paietta, Elisabeth
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2012, : 35 - 42
  • [46] Minimal residual disease in acute myeloid leukemia: clinical aspects
    Cluzeau, Thomas
    HEMATOLOGIE, 2020, 26 : 19 - 24
  • [47] Minimal Residual Disease Eradication with Venetoclax in Acute Myeloid Leukemia
    Coltoff, Alexander
    Jurcic, Joseph G.
    Campbell, Peter
    Lee, Daniel J.
    Heaney, Mark L.
    Lamanna, Nicole
    Rosenblat, Todd L.
    Frattini, Mark G.
    Vlad, George
    BLOOD, 2020, 136
  • [48] Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy
    Sebastian Schwind
    Madlen Jentzsch
    Enrica Bach
    Sebastian Stasik
    Christian Thiede
    Uwe Platzbecker
    Current Treatment Options in Oncology, 2020, 21
  • [49] Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy
    Schwind, Sebastian
    Jentzsch, Madlen
    Bach, Enrica
    Stasik, Sebastian
    Thiede, Christian
    Platzbecker, Uwe
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (01)
  • [50] Universal monitoring of minimal residual disease in acute myeloid leukemia
    Coustan-Smith, Elaine
    Song, Guangchun
    Shurtleff, Sheila
    Yeoh, Allen Eng-Juh
    Chng, Wee Joo
    Chen, Siew Peng
    Rubnitz, Jeffrey E.
    Pui, Ching-Hon
    Downing, James R.
    Campana, Dario
    JCI INSIGHT, 2018, 3 (09)